PT - JOURNAL ARTICLE AU - Jay P. Ross AU - Fulya Akçimen AU - Calwing Liao AU - Karina Kwan AU - Daniel E. Phillips AU - Zoe Schmilovich AU - Dan Spiegelman AU - Angela Genge AU - Nicolas Dupré AU - Patrick A. Dion AU - Sali M.K. Farhan AU - Guy A. Rouleau TI - Rare and common variant analyses of amyotrophic lateral sclerosis in the French-Canadian genome AID - 10.1101/2022.08.11.22278628 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.11.22278628 4099 - http://medrxiv.org/content/early/2022/08/13/2022.08.11.22278628.short 4100 - http://medrxiv.org/content/early/2022/08/13/2022.08.11.22278628.full AB - The genetic etiology of ALS includes few rare, large-effect variants and potentially many common, small-effect variants per case. The genetic risk liability for ALS might require a threshold comprised of a certain amount of variants. Here, we tested the degree to which risk for ALS was affected by rare variants in ALS genes, polygenic risk score, or both. 335 ALS cases and 356 controls from Québec, Canada were concurrently tested by SNP-chip genotyping and targeted sequencing of known ALS genes. ALS GWAS summary statistics were used to estimate an ALS PRS. Cases and controls were subdivided into rare variant carriers and non-carriers. Risk for ALS was significantly associated with PRS and rare variants independently, but the interaction was not significant. ALS PRS affected risk only in those not carrying a rare variant, suggesting that rare variants in ALS genes are generally sufficient for disease risk. Rather than modifying the penetrance of rare variants, ALS PRS is most informative in the absence of these variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the ALS Society of Canada, Brain Canada, and the Canadian Institutes of Health Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Montreal Neurological Institute and Hospital Ethics committee of McGill University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequencing results will be available on the NCBI SRA database (accession to be determined after publication).